**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 69861

**Manuscript Type:** MINIREVIEWS

**Review on hepatitis B virus precore/core promoter mutations and their correlation with genotypes and liver disease severity**

Kumar R. HBV preC/C mutations and liver disease

Rajesh Kumar

**Rajesh Kumar,** Department of School Education, Haryana Government, Panchkula 134109, Haryana, India

**Author contributions:** Kumar R wrote, edit the paper and proofread the paper.

**Corresponding author: Rajesh Kumar, Lecturer,** Department of School Education, Haryana Government, Karsa Dod, Karnal, Panchkula 134109, Haryana, India. mokhria79@gmail.com

**Received:** July 14, 2021

**Revised:** September 4, 2021

**Accepted:** March 25, 2022

**Published online:** April 27, 2022

**Abstract**

Of 350 million people worldwide are chronically infected with hepatitis B virus (HBV) and are at risk of developing cirrhosis and hepatocellular carcinoma (HCC) later in life. HBV is the most diverse DNA virus, and its genome is composed of four open reading frames: Presurface antigen/surface antigen gene (preS/S), precore/core gene (preC/C), polymerase gene (P), and the X gene (X). HBV produces quasispecies naturally or in response to antiviral agents because of the absence of proofreading activity amid reverse transcription and a high replication rate. The virus has 10 genotypes (A to J) with different geographical distributions. There are various HBV mutations in the HBV genome, including preC/C mutations, preS/S mutations, P gene mutations, and X gene mutations.The core promoter region plays a vital part in the replication, morphogenesis and pathogenesis of the virus. The precore region also plays a crucial role in viral replication. Both core promoter and precore mutations rescue the virus from host immune surveillance and result in the formation of mutated strains that may have altered pathogenicity. preC/C mutations are associated with liver disease progression. Precore mutations stop hepatitis B e antigen (HBeAg) production and basal core promoter mutations downregulate HBeAg production. Mutations in the basal core promoter are also associated with increased HBV replication and an increased incidence of advanced liver diseases such as cirrhosis and HCC. The emergence of antiviral-resistant mutations is the main reason for treatment failure. This review focuses mainly on preC/C promoter mutations and their correlation with genotypes and liver disease severity. Thorough perception and knowledge of HBV genetic variety and mutants could be vital to discover techniques for the prognosis and control of HBV infection.

**Key Words:** Hepatitis B virus; Hepatitis B virus e antigen; Hepatocellular carcinoma; Basal core promoter; Core promoter region; Precore region; Fulminant hepatitis; Acute hepatitis

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Kumar R. Review on hepatitis B virus precore/core promoter mutations and their correlation with genotypes and liver disease severity. *World J Hepatol* 2022; 14(4): 708-718

**URL:** https://www.wjgnet.com/1948-5182/full/v14/i4/708.htm

**DOI:** https://dx.doi.org/10.4254/wjh.v14.i4.708

**Core Tip:** Worldwide, 350 million people are chronically infected with hepatitis B virus and are at risk for cirrhosis and hepatocellular carcinoma. Both core promoter and precore mutations help rescue the virus from host immune surveillance and result in the formation of mutated strains that may have altered pathogenicity. Precore/core promoter (preC/C) mutations are associated with advanced liver disease. We discuss mainly preC/C mutations and their correlation with genotypes and liver disease severity.

**INTRODUCTION**

The hepatitis B virus (HBV) epidemic exists as a leading public health issue worldwide even with the accessibility of effective vaccines[1,2]. Worldwide, almost 350 million people are chronically infected with HBV and it accounts for more than 1 million deaths as a result of progressive liver diseases like cirrhosis and hepatocellular carcinoma (HCC)[3]. Persistent HBV infection leads to various clinical manifestations like inactive carrier state, chronic hepatitis, cirrhosis, and HCC[3].

HBV is an enveloped virus of the *Hepadnaviridae* family. The genome of this virus has partially double-stranded circular DNA of around 3200 nucleotides. There are four overlapping open reading frames (ORFs) that make up the polymerase (P), core (C), surface antigen (S), and X protein[4-7].

Based on an intergroup divergence of more than 7.5% in its complete genome, this virus can be divided into nine genotypes (A to I)[8,9], and based on nucleotide divergence of more than 4%, these genotypes are further subdivided into subgenotypes[8,9]. A to H have long been established as individual genotypes. Two new genotypes (I and J) were suggested more recently[10,11]. Evidence supports that HBV genotypes play a significant role in deciding HBV disease severity. Several studies have revealed that genotype A evolves more rapidly than genotype D, which causes challenges for treatment[12]. In addition, genotype-C-infected patients have more advanced liver disease than patients infected with genotype B[13]. Genotype-F-infected patients have higher mortality than patients infected with genotype A or D[14]. In an Indian study, genotype D was related to more advanced liver disease than other genotypes were[15]. In a study from the United States, genotype D acted as an independent risk factor for fulminant hepatitis (FH)[16]. In another study, genotype-F-infected patients had a higher rate of liver-related death than genotype-D-infected patients had[17]. Generally, patients infected with genotype C and D are more associated with liver disease severity (HCC) than patients infected with genotype A and B[18].

Replication in HBV occurs by reverse transcription of RNA intermediates. This virus has a high error rate during reverse transcription, leading to various mutations in the HBV genome[19]. These mutations have clinical and epidemiological significance. Various mutations (preC/C and preS/S deletion) are related to advanced liver disease and the possibility of HCC[19]. The basal core promoter (BCP) and precore mutations are frequently appearing natural variants of HBV. In this review, we discuss preC/C mutations and their correlation with genotypes and severity of liver disease.

**HBV CORE PROMOTER MUTATIONS AND RELATEDNESS WITH GENOTYPE AND ADVANCEMENT OF LIVER DISEASE**

***Core promoter region***

The CP region (nt 1575-1849) of the virus genome plays a vital part in the replication and morphogenesis of the virus[20]. CP region controls transcriptional initiation for the synthesis of the precore mRNA and pregenomic RNA (pgRNA). The CP region includes BCP (nt 1743-1849) and upper regulatory region (URR, nt 1613-1742). BCP has a crucial role in the replication of virus by promoting the formation of precore and pgRNAs[20]. The URR contains positive and negative regulatory elements that regulate activity of the promoter[20]. Hence, core promoter mutations may have an impact on virus gene expression and/or replication, and contribute to viral pathogenesis. Now, we discuss various core promoter mutations and their correlation with genotypes and the advancement of liver disease.

***A1762T/G1764A double mutation***

A1762T/G1764A double mutation is the most commonly observed core promoter mutation and it is associated with hepatitis B e antigen (HBeAg) negativity and one of the causes of advanced liver disease. There are various observations associated with this double mutation described below.

Kim *et al*[21] observed the role played by the precore mutation G1896A and the BCP double mutation A1762T/G1764A in the progression of HBV-related liver diseases. BCP double mutation A1762T/G1764A may prevent the formation of HBeAg by inserting a premature stop codon into the concerned ORF or may enhance the pgRNA transcription by evacuating of the nuclear-receptor-binding motif and led to the feeble immune response that causes HCC[22,23]. From transfection studies, it was observed that HBeAg negativity caused by BCP double mutation A1762T/G1764A was linked with serious liver disease[24].

BCP mutant may increase the host immune response towards HBV-infected hepatocytes by reducing circulating HBeAg, leading to apoptosis and regeneration of hepatocytes, which contribute to liver injury[22,25]. In an *in vivo* study, A1762T/G1764A mutant was related to cytoplasmic positioning of intracellular HB core antigen, which were strongly linked with active necroinflammation of hepatocytes[26]. The A1762T/G1764A double mutation was found to influence the amino acid sequence of X gene of HBV, upregulating [S-phase kinase-associated protein 2](https://www.sciencedirect.com/topics/medicine-and-dentistry/s-phase-kinase-associated-protein-2%22%20%5Co%20%22Learn%20more%20about%20S%20Phase%20Kinase%20Associated%20Protein%202%20from%20ScienceDirect%27s%20AI-generated%20Topic%20Pages) and downregulating its target, [cyclin](https://www.sciencedirect.com/topics/medicine-and-dentistry/proliferating-cell-nuclear-antigen%22%20%5Co%20%22Learn%20more%20about%20Proliferating%20Cell%20Nuclear%20Antigen%20from%20ScienceDirect%27s%20AI-generated%20Topic%20Pages) [kinase inhibitor](https://www.sciencedirect.com/topics/medicine-and-dentistry/phosphotransferase-inhibitor%22%20%5Co%20%22Learn%20more%20about%20Phosphotransferase%20Inhibitor%20from%20ScienceDirect%27s%20AI-generated%20Topic%20Pages) [p21](https://www.sciencedirect.com/topics/medicine-and-dentistry/p21%22%20%5Co%20%22Learn%20more%20about%20P21%20from%20ScienceDirect%27s%20AI-generated%20Topic%20Pages). The combined action of the above-mentioned events may lead to inhibition of precore mRNA and an increase in pgRNA transcription, followed by increased viral replication, which may finally lead to HCC[27].

It was found that A1762T/G1764A mutation usually appeared almost 10 years before the identification of HCC and could be an early episode in hepatocarcinogenesis[28]. The BCP double mutation A1762T/G1764A was found to be related to more progression of HCC[29] independently of HBV genotype[24,30] and viral load[30,31]. The mutations A1762T, G1764A, and A1762T/G1764A played a vital part in the progression of chronic HBV infection to HCC[25,32,33]. In a study fromEast Kalimantan, Indonesia, BCP mutations, mainly the double mutation A1762T/G1764A and T1753V, were linked with the risk of advanced liver disease (ALD)[34].

HCC patients with genotype C had more chance of carrying the A1762T/G1764A double mutation than those with genotype B[35]. In China, A1762T/G1764A mutation is a familiar mutation and found generally in HBeAg-negative chronic hepatitis B patients with genotype C and may be related to the progression of chronic HBV infection[36]. In a study on HBV-infected children in China, the frequency of BCP mutations in genotype C samples was significantly higher than that of genotype B samples[37]. From a Taiwanese study, genotype C and A1762T/G1764A mutations may be the cause of liver cirrhosis and could act as molecular markers for the diagnosis of the clinical symptoms of chronic HBV disease[38]. From a North Indian study, genotype-D-infected patients had more advanced liver disease and higher frequency of BCP mutations A1762T/G1764A than patients infected with genotype A had[39].

A1762T/G1764A mutation also acted as a significant viral marker for cirrhosis development[40]. From a study of chronic HBV infection, it was observed that A1762T/G1764A mutation was an independent factor for advancement to cirrhosis instead of HCC[41]. Table 1 showed various qualitative and quantitative factors associated with HBV-related HCC.

***1753 mutation***

1753V (V represents C/A/G) is one of core promoter mutations that is associated with advanced liver diseases like cirrhosis and HCC. In a study fromEast Kalimantan, Indonesia, BCP mutations, mainly the double mutation A1762T/G1764A and T1753V, were linked with the risk of ALD[34]. BCP T1753V mutation was associated with an increased risk of HCC[28]. The T1753C mutation was treated as one of the hot spot mutations of the protein-X encoding gene[28] and was shown to increase the transactivation and antiproliferation activity of protein X in HBV genotype D and led to carcinogenesis[42]. In a study on HBeAg-positive genotype C1 carriers, 1753 mutation was detected as a prognostic factor for HCC[28].

In a study from China, T1753V mutation in combination with BCP A1762T/G1764A double mutation was assumed to be related to HCC progression, notably in HBV/C1-infected patients[43]. In a Mongolian study, patients infected with HBV/D, C1752, and/or T1753V mutation were found to be related to HCC[42]. In a study from Southern Guangxi, China, BCP mutations were associated with HCC risk and the add-on impacts of A1762T/G1764A double mutations and T1753V mutations along with dietary aflatoxin B1 exposure for HCC risk[44]. In a study from Chiba, Japan, preC mutation (A1896) and CP mutations (T1753V and 1754) were observed more often in FH patients than in acute self-limited hepatitis patients[45]. In a study from Taiwan, the frequency of genotype C and frequency of various mutations (A1762T/ G1764A, T1753C, T1766/A1768, and A1896) increased and the frequency of various mutations (T/G1752, T1773, G1799, and C1858) declined with advancing liver diseases[38].

T to C/A mutation at nt 1753 in BCP and G to A mutation at nt 1899 in the precore region were more frequently found in liver cirrhosis patients than in the other clinical states[46]. 1653T/1753C mutation may be observed as a marker for hepatic failure[47].

***1757 mutation***

1757 mutation is one of the core promoter mutations. It is associated with the severity of liver disease. G1757 mutation and BCP A1762T/G1764A double mutation are directly linked with the high level of serum HBV DNA[48]. Various CP mutations (M1386, T1485, B1499, A1613, T1653, G1727, A1757/T1764/G1766, G or C1753, T1773, and T1766/A1768) are related to progression to HCC. These mutations individually and/or in combination are prognostic markers of HCC[49-51].

***1764/1766 mutation***

1764/1766 mutation is one of the core promoter mutations. It is associated with patients with severe liver disease. 1762/1764/1766 and 1753/1762/1764/1766 mutations showed increased viral replication and decreased HBeAg expression compared with 1762/1764 mutations alone; however, 1753/1762/1764 mutant showed only a small decrease in HBeAg expression like that of 1762/1764 mutant. So, core promoter mutations other than mutation (1762 and 1764) can have an influence on viral DNA replication and HBeAg expression[52].

***1809-1812 mutation***

1809-1812 mutations (Kozak region mutations) are responsible for HBeAg negativity and are found mainly in genotype A; subgenotype A1. Several mutations can reduce HBeAg expression: 1762T1764A mutation at the transcriptional level; 1809-1812 mutations at the translational level and 1862T mutation at the post-translational level. A1762T/G1764A mutation and 1809-1812 mutations cumulatively reduce HBeAg expression[53]. In a study from Kenya, mutations in the Kozak region (1809-1812) or precore start codon (1814-1816) were responsible for HBeAg-negativity in patients with subgenotype A1[54]. Table 2 shows the clinical potency of frequently found BCP mutations.

**HBV PRECORE MUTATIONS AND RELATEDNESS WITH GENOTYPE AND ADVANCEMENT OF LIVER DISEASE**

***Precore region***

The precore gene spans the length from nt 1814 to 1901. This region has the start site for synthesis of pgRNA, direct repeat 1, and RNA encapsidation signal. The precore region plays a crucial role in viral replication. The presence of mutations in this region disrupts viral replication and results in the formation of defective replicative intermediates. These replicative intermediates (which are not encapsidated) in hepatocytes, increase the chances for integration of HBV DNA into chromosomal DNA and lead to advanced liver disease like HCC[55].

***1896 mutation***

1896 mutation is the one of most important precore mutations. It causes HBeAg negativity and advanced liver diseases like HCC. Moreover,the precore mutation G1896A and BCP double mutation A1762T/G1764A play a significant part in the progression of HBV-related liver diseases[21]. The precore region mutation G1896A is one of the most frequently observed mutations in ALD and chronic HBV patients[56].

The G1896A mutation gives rise to a premature stop codon and reduces HBeAg synthesis. This mutation stops HBeAg formation by checking the translation of HBeAg, and the existence of a stop codon mutation may be a cause of immune evasion[56,57]. The most commonly observed precore mutation, G1896A, stops HBeAg formation by substitution of a tryptophan residue at amino acid position 28 with a premature stop codon[58]. This mutation was observed in more than 50% of individuals with chronic hepatitis B in Asia and the Mediterranean area[58]. This mutation suppresses HBeAg production, thus causing increased HBV replication and liver disease progression[21,59,60]. Precore 1858-1896 mutations are related to high serum HBV DNA levels[61].

In a meta-analysis among Asians, G1896A mutation was found to be related to a greater chance of HCC and liver disease severity[62]. Various mutations and combinations, notably at nt 1762/1764 and nt 1896/1899 in the BCP-preC region were observed to induce HBeAg negativity, liver function impairment, and HCC progression[63]. In some of the studies listed below, G1896A mutation was associated with less severity of liver disease. In a study from Taiwan, the G1896A mutation was linked with a low HCC risk[64].

***1858 mutation***

1858 mutation is one of the precore mutations and is related to greater liver disease severity. In a study from Vietnam, genotype-C-infected patients contained a high rate of C-1858 mutation (70%) and it could play a decisive role in generating severe chronic liver disease[65].

1858C mutation was found to be related to A, F and H genotypes, and 1858T mutation with B, D and E genotypes[66]. C-1858 strains may be more infectious, but more investigations are required to determine the pathogenesis of this strain[67]. High serum HBV DNA level was related to precore 1858-1896 mutations. These BCP/precore mutations may act as a prognostic marker for HBV DNA increase[61]. TCC at positions 1856 to 1858 of the precore region of HBV might cause more severe liver disease than other HBV strains with genotype C[68].

The presence of C rather than T at nt 1858 prevents G1896A mutation because the above-mentioned mutations diminish the stem-loop structure of the RNA encapsidation signal. So, CCC polymorphism and 1896 mutation are mutually exclusive[69]. HBV-infected patients with C at nt 1858 have a greater prevalence of core promoter mutations, while patients infected with T at position 1858 have only precore stop codon mutations[70].

***1862 mutation***

1862 mutation is one of the precore mutations and is one of the leading causes of HBeAg negativity and advanced liver diseases. In a study on Chinese patients, G1862T mutation caused an amino acid change in codon 17 of the precore protein; a part of the signal peptidase recognition motif. G1862T mutations were found only in genotype-B-infected patients. These variants have reduced capacity to form HBeAg and the absence of or reduced HBeAg may be a causative factor in fulminant disease. G1862 mutation is observed more in FH patients than in chronic carriers[71].

G1862 mutation is mainly found in HBV genotype A (sub-genotype A1). G1862T mutation is associated with HBeAg negativity and low viremia level in genotype-A-infected patients[21]. Saha *et al*[72] reported in an East India study that all HBV/A1 isolates had G1862T mutation regardless of HBeAg status. So, the G1862T variant might present a natural mutation in HBV/A1 isolates.

***1888 mutation***

1888 mutation is one of the precore mutations and is found only in subgenotype A1 and causes HBeAg negative serostatus. The linked loci 1809-1812, 1862 and 1888 are observed regularly in subgenotype A1 and they cause inhibition of HBeAg expression[53]. The 1888A mutation is related to HBV subgenotype A1 and it expresses a start codon upstream from the core ORF and can influence the core protein expression, resulting in lowering of viral level[73].

***1915 mutation***

1915 mutation is one of the precore mutations and is reported as one of the HCC survival mutations. Xie *et al*[74] observed five different mutations in the preC/C region (1915, 2134, 2221, 2245 and 2288) and these mutations act as independent predictors of HCC survival. Various newly reported preC/C promoter mutations (1690A, 1695A/T/G, 1700A/C, 1703C, 1850A and 1915A/G) were observed in HBV-infected isolates of Punjab state (North India)[75].

***Scanty/rare mutations***

Some rare mutations in preC/C promoter region are described below, which contribute to the severity of liver disease. Mutations in the enhancer II/BCP regions (C1653T, T1674C/G, T1753V, A1762T/G1764A and C1766T/T1768A) and mutations in the precore region (G1899A, C2002T, A2159G, A2189C and G2203A/T) are significantly associated with an increased risk of HCC[76]. Various newly reported individual/combination mutations of the X/precore region in HBV genotype D1 act as markers of HCC[50]. These mutations are T1673/G1679, G1727, C1741, C1761, A1757/T1764/G1766, T1773, T1773/G1775 and C1909[50]. Numerous core promoter mutations, 1653T, 1753V, A1762T, G1764A, 1766T and 1768A, have been observed regularly in HCC patients[77].

In an *in vitro* study, individual mutations in the BCP/precore region, T1753V (C/A/G), C1766T, T1768A, G1862T and G1899A, were linked with enhanced viral replication and/or reduced HBeAg expression and related with acute liver failure in some instances[16,52,71,78]. Ren *et al*[79] observed that individual mutations, T1753V (C/A/G), A1762T, G1764A, G1896A and G1899A, were more regularly detected in hepatitis-B-related acute-on-chronic liver failure (ACLF) than chronic hepatitis B (CHB) patients. Patients with precore mutations have a greater risk of a fatal outcome.

Tsai *et al*[80] reported that triple BCP mutation 1762/1764/1766 was related to the maximum increase in pgRNA transcription, while 1762/1764 double mutation was not so effective. T1846 and A/G1913 mutations are linked with ACLF in patients infected with genotypes B and C[81]. In Table 3 various precore/CP mutations and their correlation with clinical outcomes are shown.

**Discussion and future perspectives**

HBV genotypes and viral mutations have a fair connection for various clinical conditions of CHB and this information should be utilized to predict likely clinical course, *e.g.,* lengthy duration of HBeAg phase and more risk of progression to cirrhosis in genotype C and increased risk of HCC in genotypes C and F. There is evidence to confirm the role of genotypes and subgenotypes in pathogenesis and clinical symptoms of HBV infection. HBeAg seroconversion is delayed in patients infected with genotype C compared to other genotypes[86]. So, more research is needed about the pathogenicity of genotypes E, F and H.

In addition, preS/S region mutations are related to vaccine failure, immune escape, occult HBV infection, and HCC occurrence. P region mutations may create drug resistance to nucleoside analog antivirals. Mutations in the preC/C region are associated with HBeAg negativity, immune escape, and persistent hepatitis. Mutations in the X region play a vital part in developing HCC[86]. Mutations in various parts of the HBV genome could be the reason for unwanted clinical outcomes or evasion of detection by various diagnostic procedures, thus it becomes necessary to detect these mutations for proper evaluation of patients.

Revill and Locarnini[87] observed and recommended that in patients infected with genotype B or C, BCP mutation is a significant biomarker of the risk of cirrhosis. So, identification and quantification of BCP mutants should be used for proper treatment in Asian CHB patients. More work on the importance of these mutations in other genotypes is suggested.

HBV genotypes and mutations act as useful viral biomarkers for the prognosis of disease progression and also assist clinicians to diagnose patients who can be treated mostly from interferon therapy. In the future, clinical trials classified by different genotypes/mutants should be adopted and it is essential to apply individualized treatment regimens for CHB patients.

For population health prospects, proper observation of the pervasiveness of vaccine escape and Sescape mutations is needed and more research will be required into vaccines that remain effective against mutant strains of HBV. Identification of resistance profile is important in deciding the exact antiviral agent to start therapy.

**CONCLUSION**

HBV has more genomic diversity and various HBV mutants are significantly related with response to antiviral therapy, vaccine escape, diagnostic failure, liver fibrosis, liver cirrhosis, and HCC development. Understanding the correlation between various mutations and the clinical manifestations of HBV infection should lead to advances in diagnostic strategies and therapeutic directions.

**ACKNOWLEDGMENTS**

The authors would like to thank Dr. Jitender Bhardwaj, Assistant Professor, Zoology Department, K.U., Kurukshetra for timely support.

**REFERENCES**

1 **World Health Organization.** Hepatitis B. [cited 15 July 2021]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b

2 WHO position paper on hepatitis B vaccines October 2009. [cited 15 July 2021]. Available from: https://www.who.int/immunization/Hep\_B\_key\_points\_summary\_sep09.pdf?ua=1

3 **World Health Organization.** Global Hepatitis Report 2017. [cited 15 July 2021]. Available from: https://www.who.int/publications/i/item/global-hepatitis-report-2017

4 **Al-Sadeq DW**, Taleb SA, Zaied RE, Fahad SM, Smatti MK, Rizeq BR, Al Thani AA, Yassine HM, Nasrallah GK. Hepatitis B Virus Molecular Epidemiology, Host-Virus Interaction, Coinfection, and Laboratory Diagnosis in the MENA Region: An Update. *Pathogens* 2019; **8** [PMID: 31083509 DOI: 10.3390/pathogens8020063]

5 **Kay A**, Zoulim F. Hepatitis B virus genetic variability and evolution. *Virus Res* 2007; **127**: 164-176 [PMID: 17383765 DOI: 10.1016/j.virusres.2007.02.021]

6 **Liu C**, Fan G, Wang Z, Chen HS, Yin CC. Allosteric conformational changes of human HBV core protein transform its assembly. *Sci Rep* 2017; **7**: 1404 [PMID: 28469174 DOI: 10.1038/s41598-017-01568-9]

7 **Dryden KA**, Wieland SF, Whitten-Bauer C, Gerin JL, Chisari FV, Yeager M. Native hepatitis B virions and capsids visualized by electron cryomicroscopy. *Mol Cell* 2006; **22**: 843-850 [PMID: 16793552 DOI: 10.1016/j.molcel.2006.04.025]

8 **Kramvis A**. Genotypes and genetic variability of hepatitis B virus. *Intervirology* 2014; **57**: 141-150 [PMID: 25034481 DOI: 10.1159/000360947]

9 **Pourkarim MR**, Amini-Bavil-Olyaee S, Kurbanov F, Van Ranst M, Tacke F. Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. *World J Gastroenterol* 2014; **20**: 7152-7168 [PMID: 24966586 DOI: 10.3748/wjg.v20.i23.7152]

10 **Tran TT**, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. *J Virol* 2008; **82**: 5657-5663 [PMID: 18353958 DOI: 10.1128/JVI.02556-07]

11 **Tatematsu K**, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, Nakayoshi T, Wakuta M, Miyakawa Y, Mizokami M. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. *J Virol* 2009; **83**: 10538-10547 [PMID: 19640977 DOI: 10.1128/JVI.00462-09]

12 **Schaefer S**. Hepatitis B virus: significance of genotypes. *J Viral Hepat* 2005; **12**: 111-124 [PMID: 15720525 DOI: 10.1111/j.1365-2893.2005.00584.x]

13 **Sumi H**, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, Kanda T, Fukai K, Kato M, Saisho H. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. *Hepatology* 2003; **37**: 19-26 [PMID: 12500184 DOI: 10.1053/jhep.2003.50036]

14 **Gomes-Gouvêa MS**, Soares MCP, Bensabath G, de Carvalho-Mello IMVG, Brito EMF, Souza OSC, Queiroz ATL, Carrilho FJ, Pinho JRR. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region. *J Gen Virol* 2009; **90**: 2638-2643 [PMID: 19605587 DOI: 10.1099/vir.0.013615-0]

15 **Thakur V**, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. *J Gastroenterol Hepatol* 2002; **17**: 165-170 [PMID: 11966946 DOI: 10.1046/j.1440-1746.2002.02605.x]

16 **Wai CT**, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, Davern TJ, Lee WM, Lok AS; US Acute Liver Failure Study Group. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. *J Viral Hepat* 2005; **12**: 192-198 [PMID: 15720535 DOI: 10.1111/j.1365-2893.2005.00581.x]

17 **Sánchez-Tapias JM**, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. *Gastroenterology* 2002; **123**: 1848-1856 [PMID: 12454842 DOI: 10.1053/gast.2002.37041]

18 **Shi YH**. Correlation between hepatitis B virus genotypes and clinical outcomes. *Jpn J Infect Dis* 2012; **65**: 476-482 [PMID: 23183198 DOI: 10.7883/yoken.65.476]

19 **Chotiyaputta W**, Lok AS. Hepatitis B virus variants. *Nat Rev Gastroenterol Hepatol* 2009; **6**: 453-462 [PMID: 19581904 DOI: 10.1038/nrgastro.2009.107]

20 **Quarleri J**. Core promoter: a critical region where the hepatitis B virus makes decisions. *World J Gastroenterol* 2014; **20**: 425-435 [PMID: 24574711 DOI: 10.3748/wjg.v20.i2.425]

21 **Kim H**, Lee SA, Do SY, Kim BJ. Precore/core region mutations of hepatitis B virus related to clinical severity. *World J Gastroenterol* 2016; **22**: 4287-4296 [PMID: 27158197 DOI: 10.3748/wjg.v22.i17.4287]

22 **Tong MJ**, Blatt LM, Kao JH, Cheng JT, Corey WG. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. *Liver Int* 2007; **27**: 1356-1363 [PMID: 17900245 DOI: 10.1111/j.1478-3231.2007.01585.x]

23 **Dong Q**, Chan HL, Liu Z, Chan DP, Zhang B, Chen Y, Kung HF, Sung JJ, He ML. A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities. *Biochem Biophys Res Commun* 2008; **374**: 773-776 [PMID: 18675784 DOI: 10.1016/j.bbrc.2008.07.115]

24 **Kao JH**, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. *Gastroenterology* 2003; **124**: 327-334 [PMID: 12557138 DOI: 10.1053/gast.2003.50053]

25 **Yuan JM**, Ambinder A, Fan Y, Gao YT, Yu MC, Groopman JD. Prospective evaluation of hepatitis B 1762(T)/1764(A) mutations on hepatocellular carcinoma development in Shanghai, China. *Cancer Epidemiol Biomarkers Prev* 2009; **18**: 590-594 [PMID: 19190166 DOI: 10.1158/1055-9965.EPI-08-0966]

26 **Kim TH**, Cho EY, Oh HJ, Choi CS, Kim JW, Moon HB, Kim HC. The degrees of hepatocyte cytoplasmic expression of hepatitis B core antigen correlate with histologic activity of liver disease in the young patients with chronic hepatitis B infection. *J Korean Med Sci* 2006; **21**: 279-283 [PMID: 16614514 DOI: 10.3346/jkms.2006.21.2.279]

27 **Huang Y**, Tong S, Tai AW, Hussain M, Lok AS. Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. *Gastroenterology* 2011; **141**: 1412-1421, 1421.e1-1421.e5 [PMID: 21704589 DOI: 10.1053/j.gastro.2011.06.048]

28 **Liu S**, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. *J Natl Cancer Inst* 2009; **101**: 1066-1082 [PMID: 19574418 DOI: 10.1093/jnci/djp180]

29 **Martinot-Peignoux M**, Lapalus M, Laouénan C, Lada O, Netto-Cardoso AC, Boyer N, Ripault MP, Carvalho-Filho R, Asselah T, Marcellin P. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. *J Clin Virol* 2013; **58**: 401-407 [PMID: 24004660 DOI: 10.1016/j.jcv.2013.08.010]

30 **Liu CJ**, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, Chen DS. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. *J Infect Dis* 2006; **194**: 594-599 [PMID: 16897657 DOI: 10.1086/505883]

31 **Liu CJ**, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, Chen DS. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. *J Infect Dis* 2006; **193**: 1258-1265 [PMID: 16586363 DOI: 10.1086/502978]

32 **Tangkijvanich P**, Sa-Nguanmoo P, Mahachai V, Theamboonlers A, Poovorawan Y. A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. *Hepatol Int* 2010; **4**: 577-584 [PMID: 21063480 DOI: 10.1007/s12072-010-9197-z]

33 **Jin Y**, Zhu Y, Chen TY, Guo X, Zhang J, Wang JB, Chen WZ, Qian GS, Tu H. [The association of hepatitis B virus genotype and the basal core promoter mutation in Qidong, China]. *Zhonghua Gan Zang Bing Za Zhi* 2010; **18**: 511-515 [PMID: 20678441 DOI: 10.3760/cma.j.issn.1007-3418.2010.07.010]

34 **Wahyuni RM**, Utsumi T, Juniastuti, Yano Y, Murti IS, Amin M, Yamani LN, Istimagfiroh A, Purwono PB, Soetjipto, Lusida MI, Hayashi Y. Analysis of hepatitis B virus genotype and gene mutation in patients with advanced liver disease in East Kalimantan, Indonesia. *Biomed Rep* 2019; **10**: 303-310 [PMID: 31086664 DOI: 10.3892/br.2019.1202]

35 **Fan W**, Shi B, Wei H, Du G, Song S. Comparison of hepatitis B X gene mutation between patients with hepatocellular carcinoma and patients with chronic hepatitis B. *Virus Genes* 2011; **42**: 162-170 [PMID: 21161360 DOI: 10.1007/s11262-010-0557-5]

36 **Du H**, Li T, Zhang HY, He ZP, Dong QM, Duan XZ, Zhuang H. Correlation of hepatitis B virus (HBV) genotypes and mutations in basal core promoter/precore with clinical features of chronic HBV infection. *Liver Int* 2007; **27**: 240-246 [PMID: 17311620 DOI: 10.1111/j.1478-3231.2006.01400.x]

37 **Bai JX**, Deng HJ, Huang Y. [Clinical significance and mutation characteristics in the core promoter/pre-C region of different HBV genotypes in children]. *Zhonghua Gan Zang Bing Za Zhi* 2020; **28**: 667-671 [PMID: 32911905 DOI: 10.3760/cma.j.cn501113-20200725-00424]

38 **Chen CH**, Lee CM, Lu SN, Changchien CS, Eng HL, Huang CM, Wang JH, Hung CH, Hu TH. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. *J Clin Microbiol* 2005; **43**: 6000-6006 [PMID: 16333089 DOI: 10.1128/JCM.43.12.6000-6006.2005]

39 **Sharma S**, Sharma B, Singla B, Chawla YK, Chakraborti A, Saini N, Duseja A, Das A, Dhiman RK. Clinical significance of genotypes and precore/basal core promoter mutations in HBV related chronic liver disease patients in North India. *Dig Dis Sci* 2010; **55**: 794-802 [PMID: 20043209 DOI: 10.1007/s10620-009-1083-y]

40 **Tseng TC**, Liu CJ, Yang HC, Chen CL, Yang WT, Tsai CS, Kuo SF, Verbree FC, Su TH, Wang CC, Liu CH, Chen PJ, Chen DS, Kao JH. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. *Gut* 2015; **64**: 292-302 [PMID: 24763132 DOI: 10.1136/gutjnl-2014-306977]

41 **Chu CM**, Lin CC, Chen YC, Jeng WJ, Lin SM, Liaw YF. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. *Br J Cancer* 2012; **107**: 2010-2015 [PMID: 23079574 DOI: 10.1038/bjc.2012.474]

42 **Elkady A**, Tanaka Y, Kurbanov F, Oynsuren T, Mizokami M. Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. *J Gastroenterol Hepatol* 2008; **23**: 474-481 [PMID: 18318825 DOI: 10.1111/j.1440-1746.2008.05321.x]

43 **Yuan J**, Zhou B, Tanaka Y, Kurbanov F, Orito E, Gong Z, Xu L, Lu J, Jiang X, Lai W, Mizokami M. Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications. *J Clin Virol* 2007; **39**: 87-93 [PMID: 17451999 DOI: 10.1016/j.jcv.2007.03.005]

44 **Xu L**, Qian G, Tang L, Su J, Wang JS. Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China. *J Hepatol* 2010; **53**: 671-676 [PMID: 20650537 DOI: 10.1016/j.jhep.2010.04.032]

45 **Imamura T**, Yokosuka O, Kurihara T, Kanda T, Fukai K, Imazeki F, Saisho H. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. *Gut* 2003; **52**: 1630-1637 [PMID: 14570734 DOI: 10.1136/gut.52.11.1630]

46 **Song BC**, Cui XJ, Kim HU, Cho YK. Sequential accumulation of the basal core promoter and the precore mutations in the progression of hepatitis B virus-related chronic liver disease. *Intervirology* 2006; **49**: 266-273 [PMID: 16714855 DOI: 10.1159/000093456]

47 **Li LJ**, Ruan B, Dennin RH, Wo JE, Chen Z, Chen YG. Mutations in precore and core promoter region of HBV in patients with hepatic failure. *Hepatobiliary Pancreat Dis Int* 2002; **1**: 63-67 [PMID: 14607625]

48 **Sendi H**, Mehrab-Mohseni M, Shahraz S, Norder H, Alavian SM, Noorinayer B, Zali MR, Pumpens P, Bonkovsky HL, Magnius LO. CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA. *J Clin Virol* 2009; **46**: 259-264 [PMID: 19748824 DOI: 10.1016/j.jcv.2009.08.002]

49 **Chui SH**, Chen JH, Szeto YT, Yam WC. Prevalence of hepatitis B genotype and viral basic core promoter and precore mutations among teenagers in Macao: relationship with hepatocellular carcinoma development. *Br J Biomed Sci* 2011; **68**: 143-146 [PMID: 21950207 DOI: 10.1080/09674845.2011.11730342]

50 **Khan A**, Al Balwi MA, Tanaka Y, Hajeer A, Sanai FM, Al Abdulkarim I, Al Ayyar L, Badri M, Saudi D, Tamimi W, Mizokami M, Al Knawy B. Novel point mutations and mutational complexes in the enhancer II, core promoter and precore regions of hepatitis B virus genotype D1 associated with hepatocellular carcinoma in Saudi Arabia. *Int J Cancer* 2013; **133**: 2864-2871 [PMID: 23740667 DOI: 10.1002/ijc.28307]

51 **Qu LS**, Liu TT, Jin F, Guo YM, Chen TY, Ni ZP, Shen XZ. Combined pre-S deletion and core promoter mutations related to hepatocellular carcinoma: A nested case-control study in China. *Hepatol Res* 2011; **41**: 54-63 [PMID: 20973883 DOI: 10.1111/j.1872-034X.2010.00732.x]

52 **Parekh S**, Zoulim F, Ahn SH, Tsai A, Li J, Kawai S, Khan N, Trépo C, Wands J, Tong S. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. *J Virol* 2003; **77**: 6601-6612 [PMID: 12767980 DOI: 10.1128/jvi.77.12.6601-6612.2003]

53 **Kramvis A**, Kew MC. Molecular characterization of subgenotype A1 (subgroup Aa) of hepatitis B virus. *Hepatol Res* 2007; **37**: S27-S32 [PMID: 17627631 DOI: 10.1111/j.1872-034X.2007.00100.x]

54 **Ochwoto M**, Chauhan R, Gopalakrishnan D, Chen CY, Ng'ang'a Z, Okoth F, Kioko H, Kimotho J, Kaiguri P, Kramvis A. Genotyping and molecular characterization of hepatitis B virus in liver disease patients in Kenya. *Infect Genet Evol* 2013; **20**: 103-110 [PMID: 23978387 DOI: 10.1016/j.meegid.2013.08.013]

55 **Pahal V,** Singh J and Dadhich KS. Hepatitis B virus core promoter and precore mutations and their relatedness to genotypes and disease pathogenesis. *Adv Appl Sci Res* 2015; **7**:70-80

56 **Suppiah J**, Mohd Zain R, Bahari N, Haji Nawi S, Saat Z. G1896A Precore Mutation and Association With HBeAg Status, Genotype and Clinical Status in Patients With Chronic Hepatitis B. *Hepat Mon* 2015; **15**: e31490 [PMID: 26587040 DOI: 10.5812/hepatmon.31490]

57 **Marcellin P**. Hepatitis C: the clinical spectrum of the disease. *J Hepatol* 1999; **31** Suppl 1: 9-16 [PMID: 10622554 DOI: 10.1016/s0168-8278(99)80368-7]

58 **Tong S**, Kim KH, Chante C, Wands J, Li J. Hepatitis B Virus e Antigen Variants. *Int J Med Sci* 2005; **2**: 2-7 [PMID: 15968333 DOI: 10.7150/ijms.2.2]

59 **Carman WF**, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. *Lancet* 1989; **2**: 588-591 [PMID: 2570285 DOI: 10.1016/s0140-6736(89)90713-7]

60 **Alexopoulou A**. Mutants in the precore, core promoter, and core regions of Hepatitis B virus and their clinical relevance. *Ann Gastroenterol* 2009; **22**: 13-23

61 **Castelain S**, Descamps V, Brochot E, Helle F, Duverlie G, Nguyen-Khac E, François C. High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients. *Arch Virol* 2017; **162**: 1913-1920 [PMID: 28289975 DOI: 10.1007/s00705-017-3312-6]

62 **Liao Y**, Hu X, Chen J, Cai B, Tang J, Ying B, Wang H, Wang L. Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. *PLoS One* 2012; **7**: e38394 [PMID: 22675557 DOI: 10.1371/journal.pone.0038394]

63 **Wang W**, Shu Y, Bao H, Zhao W, Wang W, Wang Q, Lei X, Cui D, Yan Z. Genotypes and Hot Spot Mutations of Hepatitis B Virus in Northwest Chinese Population and Its Correlation with Diseases Progression. *Biomed Res Int* 2019; **2019**: 3890962 [PMID: 31886206 DOI: 10.1155/2019/3890962]

64 **Yang HI**, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ; REVEAL-HBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. *J Natl Cancer Inst* 2008; **100**: 1134-1143 [PMID: 18695135 DOI: 10.1093/jnci/djn243]

65 **Huy TT**, Ushijima H, Quang VX, Ngoc TT, Hayashi S, Sata T, Abe K. Characteristics of core promoter and precore stop codon mutants of hepatitis B virus in Vietnam. *J Med Virol* 2004; **74**: 228-236 [PMID: 15332271 DOI: 10.1002/jmv.20175]

66 **Kramvis A**, Arakawa K, Yu MC, Nogueira R, Stram DO, Kew MC. Relationship of serological subtype, basic core promoter and precore mutations to genotypes/subgenotypes of hepatitis B virus. *J Med Virol* 2008; **80**: 27-46 [PMID: 18041043 DOI: 10.1002/jmv.21049]

67 **Söderström A**, Norkrans G, Conradi N, Krantz M, Horal P, Lindh M. Histologic activity of childhood chronic hepatitis B related to viremia levels, genotypes, mutations, and epidemiologic factors. *J Pediatr Gastroenterol Nutr* 2002; **35**: 487-494 [PMID: 12394372 DOI: 10.1097/00005176-200210000-00006]

68 **Chan HL**, Tse CH, Ng EY, Leung KS, Lee KH, Tsui SK, Sung JJ. Phylogenetic, virological, and clinical characteristics of genotype C hepatitis B virus with TCC at codon 15 of the precore region. *J Clin Microbiol* 2006; **44**: 681-687 [PMID: 16517839 DOI: 10.1128/JCM.44.3.681-687.2006]

69 **Kramvis A**, Bukofzer S, Kew MC, Song E. Nucleic acid sequence analysis of the precore region of hepatitis B virus from sera of southern African black adult carriers of the virus. *Hepatology* 1997; **25**: 235-240 [PMID: 8985297 DOI: 10.1002/hep.510250143]

70 **Chan HL**, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. *Hepatology* 1999; **29**: 976-984 [PMID: 10051506 DOI: 10.1002/hep.510290352]

71 **Hou J**, Lin Y, Waters J, Wang Z, Min J, Liao H, Jiang J, Chen J, Luo K, Karayiannis P. Detection and significance of a G1862T variant of hepatitis B virus in Chinese patients with fulminant hepatitis. *J Gen Virol* 2002; **83**: 2291-2298 [PMID: 12185284 DOI: 10.1099/0022-1317-83-9-2291]

72 **Saha D**, Pal A, Biswas A, Panigrahi R, Sarkar N, Das D, Sarkar J, Guha SK, Saha B, Chakrabarti S, Chakravarty R. Molecular characterization of HBV strains circulating among the treatment-naive HIV/HBV co-infected patients of eastern India. *PLoS One* 2014; **9**: e90432 [PMID: 24587360 DOI: 10.1371/journal.pone.0090432]

73 **Kimbi GC**, Kramvis A, Kew MC. Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. *J Gen Virol* 2004; **85**: 1211-1220 [PMID: 15105537 DOI: 10.1099/vir.0.19749-0]

74 **Xie Y**, Liu S, Zhao Y, Zhang L, Zhao Y, Liu B, Guo Z. Precore/Core Region Mutations in Hepatitis B Virus DNA Predict Postoperative Survival in Hepatocellular Carcinoma. *PLoS One* 2015; **10**: e0133393 [PMID: 26208136 DOI: 10.1371/journal.pone.0133393]

75 **Kumar R**, Singh J. High frequency of precore and core promoter mutations in HBV infected population of Punjab in North India. *Int J Curr Microbiol App Sci* 2014; **3**(12): 583-597

76 **Lee JH**, Han KH, Lee JM, Park JH, Kim HS. Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection. *Clin Vaccine Immunol* 2011; **18**: 914-921 [PMID: 21490166 DOI: 10.1128/CVI.00474-10]

77 **Bai X**, Zhu Y, Jin Y, Guo X, Qian G, Chen T, Zhang J, Wang J, Groopman JD, Gu J, Tu H. Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma. *Carcinogenesis* 2011; **32**: 63-68 [PMID: 20876702 DOI: 10.1093/carcin/bgq195]

78 **Sainokami S**, Abe K, Sato A, Endo R, Takikawa Y, Suzuki K, Okamoto H. Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection. *J Gastroenterol* 2007; **42**: 241-249 [PMID: 17380283 DOI: 10.1007/s00535-006-1997-5]

79 **Ren X**, Xu Z, Liu Y, Li X, Bai S, Ding N, Zhong Y, Wang L, Mao P, Zoulim F, Xu D. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. *J Viral Hepat* 2010; **17**: 887-895 [PMID: 20070500 DOI: 10.1111/j.1365-2893.2009.01254.x]

80 **Tsai A**, Kawai S, Kwei K, Gewaily D, Hutter A, Tong DR, Li J, Wands JR, Tong S. Chimeric constructs between two hepatitis B virus genomes confirm transcriptional impact of core promoter mutations and reveal multiple effects of core gene mutations. *Virology* 2009; **387**: 364-372 [PMID: 19327810 DOI: 10.1016/j.virol.2009.03.002]

81 **Yan T**, Li K, Li F, Su H, Mu J, Tong S, Patel M, Xia J, Wands JR, Wang H. T1846 and A/G1913 are associated with acute on chronic liver failure in patients infected with hepatitis B virus genotypes B and C. *J Med Virol* 2011; **83**: 996-1004 [PMID: 21503912 DOI: 10.1002/jmv.22067]

82 **Buckwold VE**, Xu Z, Yen TS, Ou JH. Effects of a frequent double-nucleotide basal core promoter mutation and its putative single-nucleotide precursor mutations on hepatitis B virus gene expression and replication. *J Gen Virol* 1997; **78**: 2055-2065 [PMID: 9267007 DOI: 10.1099/0022-1317-78-8-2055]

83 **Brunetto MR**, Stemler M, Bonino F, Schodel F, Oliveri F, Rizzetto M, Verme G, Will H. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. *J Hepatol* 1990; **10**: 258-261 [PMID: 2332598 DOI: 10.1016/0168-8278(90)90062-v]

84 **Yin J**, Xie J, Liu S, Zhang H, Han L, Lu W, Shen Q, Xu G, Dong H, Shen J, Zhang J, Han J, Wang L, Liu Y, Wang F, Zhao J, Zhang Q, Ni W, Wang H, Cao G. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. *Am J Gastroenterol* 2011; **106**: 81-92 [PMID: 20959817 DOI: 10.1038/ajg.2010.399]

85 **Inoue J**, Ueno Y, Nagasaki F, Wakui Y, Kondo Y, Fukushima K, Niitsuma H, Shimosegawa T. Enhanced intracellular retention of a hepatitis B virus strain associated with fulminant hepatitis. *Virology* 2009; **395**: 202-209 [PMID: 19850315 DOI: 10.1016/j.virol.2009.09.028]

86 **Zhang ZH**, Wu CC, Chen XW, Li X, Li J, Lu MJ. Genetic variation of hepatitis B virus and its significance for pathogenesis. *World J Gastroenterol* 2016; **22**: 126-144 [PMID: 26755865 DOI: 10.3748/wjg.v22.i1.126]

87 **Revill P**, Locarnini S. Viral factors and predicting disease outcomes in chronic hepatitis B. *Gut* 2015; **64**: 191-193 [PMID: 24920075 DOI: 10.1136/gutjnl-2014-307398]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict of interest among authors.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 14, 2021

**First decision:** August 18, 2021

**Article in press:** March 25, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): E

**P-Reviewer:** Moldogazieva NT, Russia; Tsoulfas G, Greece; Yao HR, China **S-Editor:** Wang JJ **L-Editor:** Kerr C **P-Editor:** Wang JJ

**Table 1 Qualitative and quantitative factors and the level of each factor associated with hepatitis B virus-related hepatocellular carcinoma**

|  |  |  |
| --- | --- | --- |
| **Patient group** | **Qualitative factors** | **Quantitative factors** |
| Low risk | Genotype A/B | Low level of HBV-DNA in serum; low level of HBsAg in serum |
| High risk | Genotype C/D; BCP mutation (A1762T/G1764A); pre-S deletion | High level of HBV-DNA in serum; high level of HBsAg in serum |

HBV: Hepatitis B virus; BCP: Basal core promoter; HBsAg: Hepatitis B surface antigen.

**Table 2 Prevalent basal core promoter mutations and their clinical importance**

|  |  |
| --- | --- |
| **Nucleotide position** | **Clinical applicability** |
| A1762T + G1764A (BCP double mutant) | Chronic hepatitis; FH; decline in HBeAg formation and enhanced virus replication; high ALT; found in patients with HBV genotypes who have 1858C (i.e., genotype C) |
| A1762T | HBeAg seroconversion; histological inflammation |
| A1764A | Marginally decline in replication ability of the virus |
| 1653T | Jointly with 1762T + 1764A in FH and HCC patients |
| 1753-1757 | Jointly with the 1762T + 1764A mutation in FH and HCC patients; ALT level changes and histological changes |
| 1764A/T + 1766A/G | Jointly with 1810T + 1811T double mutation in active and inactive disease; 1762A1766A mutation, jointly with 1762T mutation, was observed in FH and HCC patients; 1764T + 1766G mutation was observed in a patient with recurrent FH after liver transplantation, although was not observed in FH patients |
| 1766T + 1768A | FH; along with A1762T + G1764A, in recurrent hepatitis patients following liver transplantation; jointly with G1764A in HBeAg-negative asymptomatic carrier; exacerbation of HBV infection  |

ALT: Alanine aminotransferase; BCP: Basal core promoter; FH: Fulminant hepatitis; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma.

**Table 3 Various precore/core promoter mutations and their clinical outcomes**

|  |  |  |
| --- | --- | --- |
| **Mutation type** | **Clinical symptoms** | **Particular mutation** |
| PC/CP mutations | HBeAg-negative. Hepatitis | T1753C[52], A1762T[82], G1764A[82], C1766T[52], T1768A[52], G1896A[59,83], G1899A[59,83] |
| HCC | C1653T[63], T1753C[63], A1762T[63,65,84], G1764A[63,65,84], G1896A[63], G1899A[63] |
| Fulminant hepatitis | A1762T[85], G1764A[85], G1862T[71,85], G1896A[85] |

PC: Precore; CP: Core promoter; HBeAg: Hepatitis B e antigen; HCC: Hepatocellular carcinoma.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**